Citations

Showing 10 of 108081 citations.

Pulse Oximetry: A Necessary Imperfect Tool in Critical Care
Athale, Janhavi, Suffredini, Anthony F.

Mayo Clinic

Critical Care Medicine | April 11, 2023 | Volume: 51 | Issue: 9 | Pages: 1246-1248

10.1097/ccm.0000000000005891 | PMID 37039519 Get It

Quantitative Sleep Electroencephalogram in Parkinson’s Disease: A Case-Control Study
Memon, Adeel , Catiul, Corina , Irwin, Zachary T. , Pilkington, Jennifer, Memon, Raima , Joop, Allen , Wood, Kimberly H. , Amara, Amy W. , Memon, Raima A, Cutter, Gary , Miocinovic, Svjetlana

Mayo Clinic

Journal of Parkinson’s Disease | April 11, 2023 | Volume: 13 | Issue: 3 | Pages: 351-365

10.3233/jpd-223565 | PMID 37066921 Get It

Background: Sleep disorders are common in Parkinson’s disease (PD) and include alterations in sleep-related EEG oscillations. Objective: This case-control study tested the hypothesis that patients with PD would have a lower density of Scalp-Slow Wave (SW) oscillations and higher slow-to-fast frequencies ratio in rapid eye movement (REM) sleep than non-PD controls. Other sleep-related quantitative EEG (qEEG) features were also examined, including SW morphology, sleep spindles, and Scalp-SW spindle phase-amplitude coupling. Methods: Polysomnography (PSG)-derived sleep EEG was compared between PD participants ( n = 56) and non-PD controls ( n = 30). Following artifact rejection, sleep qEEG analysis was performed in frontal and central leads. Measures included SW density and morphological features of SW and sleep spindles, SW-spindle phase-amplitude coupling, and spectral power analysis in Non-REM (NREM) and REM. Differences in qEEG features between PD and non-PD controls were compared using two-tailed Welch’s t-tests, and correction for multiple comparisons was performed per the Benjamini-Hochberg method. Results: SW density was lower in PD than in non-PD controls (F = 13.5, p’ = 0.003). The PD group also exhibited higher ratio of slow REM EEG frequencies (F = 4.23, p’ = 0.013), higher slow spindle peak frequency (F = 24.7, p’ < 0.002), and greater SW-spindle coupling angle distribution non-uniformity (strength) (F = 7.30, p’ = 0.034). Conclusion: This study comprehensively evaluates sleep qEEG including SW-spindle phase amplitude coupling in PD compared to non-PD controls. These findings provide novel insights into how neurodegenerative disease disrupts electrophysiological sleep rhythms. Considering the role of sleep oscillatory activity on neural plasticity, future studies should investigate the influence of these qEEG markers on cognition in PD.
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma
Spencer, Kristen , Pappas, Leontios , Baiev, Islam , Maurer, Jordan R., Bocobo, Andrea Grace, Jain, Apurva, Reyes, Stephanie , Le, Tri Minh , Rahma, Osama E. , Stanton, Jennifer R., DeLeon, Thomas, Roth, Marc, Zhu, Andrew X. , Lennerz, Jochen K. , Iafrate, A. John , Boyhen, Kylie, VanCott, Christine, Roberts, Lewis R. , Lindsey, Stacie , Goff, Laura W. , Mody, Kabir , Shroff, Rachna T. , Kelley, Robin Kate , Javle, Milind , DeLeon, Thomas T, Lennerz, Jochen , Goyal, Lipika , Roberts, Lewis R , Spencer, Kristen , Pappas, Leontios , Zhang, Karen , Jain, Apurva, De Armas, Anaemy Danner , Roth, Marc, Peters, Mary Linton B , Horick, Nora , Borad, Mitesh J. , Goyal, Lipika

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 11, 2023 | Volume: 115 | Issue: 7 | Pages: 870-880

10.1093/jnci/djad046 | PMID 37040087 Get It

Abstract Background Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in these populations, focusing on use of adjuvant, liver-directed, targeted, and investigational therapies. Methods This multicenter collaboration included patients with ICC or ECC treated at 1 of 8 participating institutions. Retrospective data were collected on risk factors, pathology, treatments, and survival. Comparative statistical tests were 2-sided. Results Among 1039 patients screened, 847 patients met eligibility (ICC = 611, ECC = 236). Patients with ECC were more likely than those with ICC to present with early stage disease (53.8% vs 28.0%), undergo surgical resection (55.1% vs 29.8%), and receive adjuvant chemoradiation (36.5% vs 4.2%) (all P &lt; .00001). However, they were less likely to undergo molecular profiling (50.3% vs 64.3%) or receive liver-directed therapy (17.9% vs 35.7%), targeted therapy (4.7% vs 18.9%), and clinical trial therapy (10.6% vs 24.8%) (all P &lt; .001). In patients with recurrent ECC after surgery, the molecular profiling rate was 64.5%. Patients with advanced ECC had a shorter median overall survival than those with advanced ICC (11.8 vs 15.1 months; P &lt; .001). Conclusions Patients with advanced ECC have low rates of molecular profiling, possibly in part because of insufficient tissue. They also have low rates of targeted therapy use and clinical trial enrollment. While these rates are higher in advanced ICC, the prognosis for both subtypes of cholangiocarcinoma remains poor, and a pressing need exists for new effective targeted therapies and broader access to clinical trials.
MASTRO I: Meta-Analysis and Systematic Review of thrombectomy stent retriever outcomes: comparing functional, safety and recanalization outcomes between EmboTrap, Solitaire and Trevo in acute ischemic stroke
Zaidat, Osama O. , Ikeme, Shelly , Yoshimura, Shinichi , Yang, Xinguang , Brinjikji, Waleed , Kallmes, David F. , Brouwer, Patrick A. , Pederson, John M. , Tarchand, Ranita , Steffenson, Annie , Touchette, Jillienne C. , Yoshimura, Shinichi , Yang, Xin-Guang , Brinjikji, Waleed , Kallmes, David F , Brouwer, Patrick , Pederson, John M , Tarchand, Ranita , Steffenson, Annie , Kallmes, Kevin M , Touchette, Jillienne , Andersson, Tommy , Ikeme, Shelly , Sheth, Sunil A , Andersson, Tommy

Mayo Clinic

Journal of Comparative Effectiveness Research | April 11, 2023 | Volume: 12 | Issue: 5 | Pages: No page available

10.57264/cer-2023-0001 | PMID 37039285 Get It

Aim: Stent-retriever (SR) thrombectomy has demonstrated superior outcomes in patients with acute ischemic stroke compared with medical management alone, but differences among SRs remain unexplored. We conducted a Systematic Review/Meta-Analysis to compare outcomes between three SRs: EmboTrap ® , Solitaire™, and Trevo ® . Methods: We conducted a PRISMA-compliant Systematic Review among English-language studies published after 2014 in PubMed/MEDLINE that reported SRs in ≥25 patients. Functional and safety outcomes included 90-day modified Rankin scale (mRS 0-2), mortality, symptomatic intracranial hemorrhage (sICH), and embolization to new territory (ENT). Recanalization outcomes included modified thrombolysis in cerebral infarction (mTICI) and first-pass recanalization (FPR). We used a random effects Meta-Analysis to compare outcomes; subgroup and outlier-influencer analysis were performed to explore heterogeneity. Results: Fifty-one articles comprising 9,804 patients were included. EmboTrap had statistically significantly higher rates of mRS 0-2 (57.4%) compared with Trevo (50.0%, p = 0.013) and Solitaire (45.3%, p < 0.001). Compared with Solitaire (20.4%), EmboTrap (11.2%, p < 0.001) and Trevo (14.5%, p = 0.018) had statistically significantly lower mortality. Compared with Solitaire (7.7%), EmboTrap (3.9%, p = 0.028) and Trevo (4.6%, p = 0.049) had statistically significantly lower rates of sICH. There were no significant differences in ENT rates across all three devices (6.0% for EmboTrap, 5.3% for Trevo, and 7.7% for Solitaire, p = 0.518). EmboTrap had numerically higher rates of recanalization; however, no statistically significant differences were found. Conclusion: The results of our Systematic Review/Meta-Analysis suggest that EmboTrap may be associated with significantly improved functional outcomes compared with Solitaire and Trevo. EmboTrap and Trevo may be associated with significantly lower rates of sICH and mortality compared with Solitaire. No significant differences in recanalization and ENT rates were found. These conclusions are tempered by limitations of the analysis including variations in thrombectomy techniques in the field, highlighting the need for multi-arm RCT studies comparing different SR devices to confirm our findings.
Non-Invasive Cardiovascular Imaging for Cardiovascular Risk Assessment in Rheumatoid Arthritis
Scanlon, Erin M. , Mankad, Rekha , Davis, John M. , Scanlon, Erin M.

Mayo Clinic

EMJ Rheumatology | April 11, 2023 | Volume: No volume available | Issue: No issue available | Pages: 106-113

10.33590/emjrheumatol/10313865 Get It

People with rheumatoid arthritis (RA) are often under-recognised as a group with elevated risk of cardiovascular (CV) disease and increased morbidity from CV events. Standard clinical risk assessment tools, which take into account traditional CV risk factors such as smoking, diabetes, hypertension, hyperlipidaemia, and family history do not accurately predict CV risk in patients with autoimmune rheumatic disorders; therefore, there is an unmet need for other methods to assess their risk. Non-invasive CV imaging is evolving as a novel clinical tool to determine subclinical atherosclerotic coronary artery disease in patients with RA. Non-invasive imaging studies, such as tests of endothelial function (i.e. reactive hyperaemia index and flow-mediated dilation) and arterial stiffness (i.e. pulse-wave velocity), have been identified as a potential means for providing accurate assessment of early CV risk in the general population and are evolving in their utility for patients with RA. These types of non-invasive imaging have the potential to eliminate the current use of invasive assessments for identification of precursors to coronary artery disease, such as coronary angiography for early endothelial cell dysfunction. By combining the expertise of subspecialists in cardio-rheumatology clinics, the expectation is to pre-emptively identify RA patients with early coronary artery disease, allowing early modification of risk factors through either medical management or lifestyle modification.
Use of the Revised Second Victim Experience and Support Tool to Examine Second Victim Experiences of Respiratory Therapists
Allender, Erica A, Bottema, Sophia M, Bosley, Christopher, Holst, Stephanie J, Clark, William J., Weaver, Amy L. , Finney, Robyn E. , Bosley, Christopher L., Rivera-Chiauzzi, Enid Y , Clark, William J, Rivera‐Chiauzzi, Enid Y. , Holst, Stephanie J.

Mayo Clinic

Respiratory Care | April 11, 2023 | Volume: 68 | Issue: 6 | Pages: 749-759

10.4187/respcare.10719 | PMID 37041030 Get It

BACKGROUND: Respiratory therapists (RTs) work alongside allied health staff, nurses, and physicians during stressful and traumatic events that can be associated with emotional and physiological implications known as second victim (SV) experiences (SVEs). This study aimed to evaluate SVEs of RTs, including both positive and negative implications. METHODS: RTs within a large academic health care organization across Minnesota, Wisconsin, Florida, and Arizona were asked to participate in an anonymous survey that included the validated Second Victim Experience and Support Tool-Revised to assess SVEs as well as desired support services. RESULTS: Of the RTs invited to participate, 30.8% (171/555) completed the survey. Of the 171 survey respondents, 91.2% (156) reported that they had been part of a stressful or traumatic work-related event as an RT, student, or department support staff member. Emotional or physiologic implications experienced by respondents as SVs included anxiety 39.1% (61/156), reliving of the event 36.5% (57/156), sleeplessness 32.1% (50/156), and guilt 28.2% (44/156). Following a stressful clinical event, 14.8% (22/149) experienced psychological distress, 14.2% (21/148) experienced physical distress, 17.7% (26/147) indicated lack of institutional support, and 15.6% (23/147) indicated turnover intentions. Enhanced resilience and growth were reported by 9.5% (14/147). Clinical and non-clinical events were reported as possible triggers for SVEs. Nearly half of respondents 49.4% (77/156) indicated feeling like an SV due to events related to COVID-19. Peer support was the highest ranked form of desired support following an SVE by 57.7% (90/156). CONCLUSIONS: RTs are involved in stressful or traumatic clinical events, resulting in psychological/physical distress and turnover intentions. The COVID-19 pandemic has had a significant impact on RTs’ SVEs, highlighting the importance of addressing the SV phenomenon among this population.
Diverging patterns of plasticity in the nucleus basalis of Meynert in early- and late-onset blindness
Parra, Carlos , Murphy, Matthew C. , Schuman, Joel S. , Nau, Amy , Chan, Kevin C. , Schuman, Joel S , Chan, Kevin C , Bang, Ji Won , Chan, Russell W.

Mayo Clinic

Brain Communications | April 11, 2023 | Volume: 5 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcad119 | PMID 37101831 Get It

Abstract Plasticity in the brain is impacted by an individual’s age at the onset of the blindness. However, what drives the varying degrees of plasticity remains largely unclear. One possible explanation attributes the mechanisms for the differing levels of plasticity to the cholinergic signals originating in the nucleus basalis of Meynert. This explanation is based on the fact that the nucleus basalis of Meynert can modulate cortical processes such as plasticity and sensory encoding through its widespread cholinergic projections. Nevertheless, there is no direct evidence indicating that the nucleus basalis of Meynert undergoes plastic changes following blindness. Therefore, using multiparametric magnetic resonance imaging, we examined if the structural and functional properties of the nucleus basalis of Meynert differ between early blind, late blind and sighted individuals. We observed that early and late blind individuals had a preserved volumetric size and cerebrovascular reactivity in the nucleus basalis of Meynert. However, we observed a reduction in the directionality of water diffusion in both early and late blind individuals compared to sighted individuals. Notably, the nucleus basalis of Meynert presented diverging patterns of functional connectivity between early and late blind individuals. This functional connectivity was enhanced at both global and local (visual, language and default-mode networks) levels in the early blind individuals, but there were little-to-no changes in the late blind individuals when compared to sighted controls. Furthermore, the age at onset of blindness predicted both global and local functional connectivity. These results suggest that upon reduced directionality of water diffusion in the nucleus basalis of Meynert, cholinergic influence may be stronger for the early blind compared to the late blind individuals. Our findings are important to unravelling why early blind individuals present stronger and more widespread cross-modal plasticity compared to late blind individuals.
Association of Preoperative Growth Differentiation Factor-15 Concentrations and Postoperative Cardiovascular Events after Major Noncardiac Surgery
Duceppe, Emmanuelle , Conen, David , Tiboni, Maria , Kavsak, Peter A. , Srinathan, Sadeesh, Pearse, Rupert M. , Jaffe, Allan S. , Heels‐Ansdell, Diane , Garg, Amit X. , Pettit, Shirley , Sapsford, Robert J., Borges, Flávia K. , Chan, Matthew T.V. , Patel, Ameen , Sessler, Daniel I. , Ofori, Sandra , Jaffe, Allan S. , Devereaux, P.J.

Mayo Clinic

Anesthesiology | April 11, 2023 | Volume: 138 | Issue: 5 | Pages: 508-522

10.1097/aln.0000000000004539 | PMID 37039711 Get It

Background The association between growth differentiation factor-15 concentrations and cardiovascular disease has been well described. The study hypothesis was that growth differentiation factor-15 may help cardiac risk stratification in noncardiac surgical patients, in addition to clinical evaluation. Methods The objective of the study was to determine whether preoperative serum growth differentiation factor-15 is associated with the composite primary outcome of myocardial injury after noncardiac surgery and vascular death at 30 days and can improve cardiac risk prediction in noncardiac surgery. This is a prospective cohort study of patients 45 yr or older having major noncardiac surgery. The association between preoperative growth differentiation factor-15 and the primary outcome was determined after adjusting for the Revised Cardiac Risk Index. Preoperative N-terminal-pro hormone brain natriuretic peptide was also added to compare predictive performance with growth differentiation factor-15. Results Between October 27, 2008, and October 30, 2013, a total of 5,238 patients were included who had preoperative growth differentiation factor-15 measured (median, 1,325; interquartile range, 880 to 2,132 pg/ml). The risk of myocardial injury after noncardiac surgery and vascular death was 99 of 1,705 (5.8%) for growth differentiation factor-15 less than 1,000 pg/ml, 161 of 1,332 (12.1%) for growth differentiation factor-15 1,000 to less than 1,500 pg/ml, 302 of 1476 (20.5%) for growth differentiation factor-15 1,500 to less than 3,000 pg/ml, and 247 of 725 (34.1%) for growth differentiation factor-15 concentrations 3,000 pg/ml or greater. Compared to patients who had growth differentiation factor-15 concentrations less than 1,000 pg/ml, the corresponding adjusted hazard ratio for each growth differentiation factor-15 category was 1.93 (95% CI, 1.50 to 2.48), 3.04 (95% CI, 2.41 to 3.84), and 4.8 (95% CI, 3.76 to 6.14), respectively. The addition of growth differentiation factor-15 improved cardiac risk classification by 30.1% (301 per 1,000 patients) compared to Revised Cardiac Risk Index alone. It also provided additional risk classification beyond the combination of preoperative N-terminal-pro hormone brain natriuretic peptide and Revised Cardiac Risk Index (16.1%; 161 per 1,000 patients). Conclusions Growth differentiation factor-15 is strongly associated with 30-day risk of major cardiovascular events and significantly improved cardiac risk prediction in patients undergoing noncardiac surgery. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New
Cardiac MRI: State of the Art
François, Christopher J. , Leiner, Tim , Rajiah, Prabhakar , François, Christopher , Leiner, Tim , Rajiah, Prabhakar

Mayo Clinic

Radiology | April 11, 2023 | Volume: 307 | Issue: 3 | Pages: No page available

10.1148/radiol.223008 | PMID 37039684 Get It

Review and standard operating procedures for collection of biospecimens and analysis of biomarkers innew onsetrefractory status epilepticus
Hanin, Aurélie , Pulluru, Yashwanth , Gopaul, Margaret , deCampo, Danielle , Howe, Charles L. , Koh, Sookyong , Taraschenko, Olga , Wilson, Michael R. , Gaspard, Nicolas , Helbig, Ingo , Howe, Charles L , Navarro, Vincent , Taraschenko, Olga , Vezzani, Annamaria , Gaspard, Nicolas , Hirsch, Lawrence J , Wilson, Michael R , Hanin, Aurelie , Cespedes, Jorge , Aronica, Eleonora , Helbig, Ingo , Hüttner, Anita , Navarro, Vincent , Vezzani, Annamaria , Xian, Julie , Hirsch, Lawrence J.

Mayo Clinic

Epilepsia | April 11, 2023 | Volume: 64 | Issue: 6 | Pages: 1444-1457

10.1111/epi.17600 | PMID 37039049 Get It

AbstractNew onset refractory status epilepticus (NORSE), including its subtype with a preceding febrile illness known as febrile infection‐related epilepsy syndrome (FIRES), is one of the most severe forms of status epilepticus. The exact causes of NORSE are currently unknown, and there is so far no disease‐specific therapy. Identifying the underlying pathophysiology and discovering specific biomarkers, whether immunologic, infectious, genetic, or other, may help physicians in the management of patients with NORSE. A broad spectrum of biomarkers has been proposed for status epilepticus patients, some of which were evaluated for patients with NORSE. Nonetheless, none has been validated, due to significant variabilities in study cohorts, collected biospecimens, applied analytical methods, and defined outcome endpoints, and to small sample sizes. The NORSE Institute established an open NORSE/FIRES biorepository for health‐related data and biological samples allowing the collection of biospecimens worldwide, promoting multicenter research and sharing of data and specimens. Here, we suggest standard operating procedures for biospecimen collection and biobanking in this rare condition. We also propose criteria for the appropriate use of previously collected biospecimens. We predict that the widespread use of standardized procedures will reduce heterogeneity, facilitate the future identification of validated biomarkers for NORSE, and provide a better understanding of the pathophysiology and best clinical management for these patients.